OASIS-5 Lower-Dose Oral Semaglutide: Affordability Bet Faces Efficacy-Proof and Payer Hurdles

Novo Nordisk Initiates OASIS-5 Trial for Lower-Dose Oral Wegovy

Novo Nordisk has initiated the late-stage OASIS-5 clinical trial to investigate the efficacy of lower oral doses of its drug, Wegovy (semaglutide), for weight reduction in adults with obesity. The 60-week randomized study will compare two unspecified lower strengths against a placebo in 450 participants with a BMI of 30 or above, or 27 with an obesity-related health issue, who have previously struggled with weight loss. This move comes amidst increasing competition in the projected $100bn obesity drug market.

• Trial Design and Objectives: The OASIS-5 trial is a 60-week, randomized study designed to compare two unspecified lower strengths of oral semaglutide against a placebo. Its primary goal is to determine if these reduced doses can lead to greater weight loss in participants compared to placebo, while secondary outcomes will assess changes in waist circumference, other health markers, and side effects.
• Patient Population and Exclusion Criteria: The study will enroll 450 adults who have a body mass index (BMI) of 30 or above, or 27 if they have an obesity-related health issue, and have previously failed to lose weight. Importantly, the trial specifically excludes patients with diabetes, those who have experienced major recent weight changes, or individuals currently undergoing GLP-1-based therapies.
• Market Context and Strategic Rationale: Novo Nordisk's decision to explore lower doses of oral Wegovy is influenced by growing competition from companies like Eli Lilly in the rapidly expanding obesity drug market, which is forecast to exceed $100 billion by 2030. The company's CEO noted that patients often use lower dosages independently, seeking benefits beyond just weight loss, suggesting a strategic move to cater to broader patient needs and market dynamics.

Addressing Current Limitations in Oral Semaglutide Dosing for Obesity

Current obesity treatment — spanning pharmacotherapy, bariatric surgery, and lifestyle intervention — is constrained by a complex web of safety, adherence, and population-specific challenges. No single modality is without meaningful limitations, and the optimal management of obesity increasingly demands individualized, multidisciplinary strategies.

• Lean mass and bone loss during weight reduction: Weight loss by any means is accompanied by loss of muscle and bone mass, necessitating concurrent protein supplementation and resistance training. Both resistance and aerobic exercise are beneficial in preventing osteopenia associated with weight loss, which may contribute to premature mortality if left unaddressed.

• Age-related treatment risks at both extremes: In elderly patients, GLP-1RAs and GIP/GLP-1RAs carry heightened risk of muscle mass loss and increased adverse event rates, requiring careful benefit–risk assessment given limited data in sarcopenic obesity. In children and adolescents, while these agents have demonstrated efficacy for weight reduction, long-term developmental consequences remain unknown.

• High prevalence of gastrointestinal adverse effects: Between 40% and 70% of patients experience GI side effects — including nausea, vomiting, diarrhea, constipation, and delayed gastric emptying — typically emerging during dose escalation. Accumulating evidence has also identified more serious GI complications such as cholelithiasis, cholecystitis, gastroparesis, and bowel obstruction, which may necessitate caution in susceptible individuals and can drive treatment discontinuation.

• Weight cycling risk associated with discontinuation: Observational evidence suggests that weight cycling may be harmful, as regained weight is predominantly fat mass; repeated cycles may paradoxically worsen obesity. This is of particular clinical concern given the high rates of discontinuation driven by cost and limited drug availability, and intermittent use for modest weight loss may ultimately be counterproductive.

• Long-term treatment dependency: Semaglutide and tirzepatide appear to require sustained use to maintain weight loss outcomes, presenting ongoing challenges related to adherence, affordability, and supply continuity.

• Post-bariatric surgery complications: Bariatric surgery carries both surgical risks — including small bowel obstruction, internal hernia, anastomotic ulcer, and anastomotic leak — and medical sequelae such as dumping syndrome, osteoporosis, nephrolithiasis, elevated suicide rates, and nutritional deficiencies that can progress to neurologic disorders. Lifelong micronutrient supplementation and regular monitoring of vitamin levels are required to prevent these outcomes.

• Limited safety data in special populations: Evidence in pregnant or lactating women, pediatric patients, and individuals with advanced renal or hepatic impairment remains insufficient, restricting the generalizability of current treatment protocols and underscoring the need for further dedicated study.

• Requirement for comprehensive, individualized care: Patient selection for novel anti-obesity pharmacotherapies should align with the eligibility criteria used in pivotal clinical trials, and pharmacological intervention must be paired with the dietary and exercise regimens employed in those trials to achieve optimal outcomes.

Unpacking the OASIS-5 Trial Design for Lower-Dose Oral Wegovy

The trials most relevant to semaglutide's role in obesity pharmacotherapy include a meta-analysis of once-weekly semaglutide versus placebo across randomized controlled trials, as well as a systematic review and meta-analysis directly comparing tirzepatide and semaglutide. These studies provide the foundational efficacy and cardiometabolic data that inform the clinical positioning of GLP-1–based therapies in obesity management.

Navigating the Evolving Obesity Treatment Landscape and Wegovy's Position

Over the past five years, the obesity treatment landscape has been fundamentally reshaped by the emergence of highly efficacious incretin-based pharmacotherapies, setting new benchmarks for clinically meaningful weight reduction. GLP-1 receptor agonists, particularly once-weekly semaglutide 2.4 mg, established early precedent by delivering mean weight loss of up to 13.9% after 68 weeks in adults without diabetes, alongside meaningful improvements in cardiometabolic parameters including waist circumference, blood pressure, lipid profiles, fasting plasma glucose, and HOMA-IR. Comparative data further reinforced semaglutide's superiority over earlier agents, with semaglutide recipients achieving significantly greater weight loss than liraglutide recipients (−14.7 ± 5.8% vs. −6.2 ± 4.9%; p < 0.001) at 68 weeks, and a markedly higher proportion attaining ≥15% body weight reduction (55% vs. 12%). The treatment paradigm subsequently advanced with the introduction of tirzepatide, a dual GLP-1/GIP receptor agonist, which demonstrated dose-dependent weight loss exceeding 20% at higher doses in randomized controlled trials — a mean difference of −16.32% versus placebo — with real-world data corroborating these findings at mean doses of 5.1 ± 1.4 mg/week.

The therapeutic frontier has continued to expand with next-generation multi-receptor agonists. Retatrutide (12 mg once weekly), a triple receptor agonist, produced weight loss of up to 22.1% after 48 weeks in clinical trials, surpassing both tirzepatide and semaglutide and signaling a new ceiling for pharmacological efficacy in obesity management. Beyond magnitude of weight loss, trials have increasingly characterized the breadth of metabolic benefit: in SURMOUNT-1, participants achieving at least 35% body weight reduction demonstrated mean changes of up to −14.2 mmHg in systolic blood pressure, −59.7% in HOMA-IR, and −0.65 percentage points in HbA1c. Importantly, real-world evidence has shown that tirzepatide achieves significant reductions in body weight and fat mass while preserving lean mass and muscle function over four months of treatment — a clinically relevant distinction as preservation of skeletal muscle becomes an increasingly scrutinized endpoint. The landscape has also broadened demographically, with network meta-analyses in pediatric populations identifying semaglutide as the most effective agent for BMI reduction in children and adolescents with obesity.

Safety data across this new generation of agents have been consistent in profile, though notable in magnitude. Gastrointestinal adverse events remain the predominant tolerability concern: tirzepatide was associated with relative risks of 3.11 for nausea, 5.94 for vomiting, 2.92 for diarrhea, and 2.85 for constipation, with discontinuation due to adverse events carrying a relative risk of 2.29. Across GLP-1 receptor agonists broadly, adverse events were reported in 80–97% of treated patients versus 63–100% with placebo, with gastrointestinal events accounting for the majority of cases. Serious adverse events across these agents were not statistically elevated in most analyses, though serious gastrointestinal events warrant ongoing pharmacovigilance. Collectively, five years of trial data have repositioned obesity pharmacotherapy from modest adjunctive intervention to a primary disease-modifying modality with measurable systemic benefit — fundamentally altering strategic and clinical expectations for the field.

Optimizing Oral Semaglutide: A Strategic Play in Obesity

The global health challenge of obesity continues to drive significant innovation in pharmacotherapy, with GLP-1 receptor agonists like semaglutide emerging as powerful tools. Novo Nordisk's decision to initiate the OASIS-5 trial, investigating lower oral doses of Wegovy, signals a strategic pivot aimed at optimizing patient experience and expanding market reach in this burgeoning therapeutic area.

Currently, oral semaglutide at 25mg has demonstrated substantial weight reduction, comparable to its injectable counterpart, yet higher doses are often associated with gastrointestinal adverse events. Furthermore, real-world data on the 14mg oral dose, while showing a favorable safety profile, highlighted considerable variability in weight loss, with many patients achieving less than 10% reduction. This new trial seeks to address these nuances by exploring whether lower oral doses can strike a better balance between efficacy and tolerability.

This move carries several strategic implications:

• Broadening Patient Access: By potentially offering a more tolerable option, Novo Nordisk could attract patients who are hesitant about injections or who cannot tolerate higher doses due to side effects, thereby expanding the overall market for semaglutide.

• Competitive Edge: In a rapidly crowding market, a differentiated offering with a range of oral doses could provide a significant competitive advantage, appealing to a wider spectrum of patient needs and preferences.

• Lifecycle Management: This trial underscores a commitment to continuous product development, ensuring semaglutide remains at the forefront of obesity management.

However, this strategy is not without risks. The primary concern is whether these lower doses will deliver clinically meaningful weight loss that satisfies patient expectations, especially given the variability seen with the 14mg dose. If efficacy is significantly compromised, it could dilute the brand's strong reputation for weight loss. The company must carefully navigate the trade-off between improved tolerability and sustained efficacy to maintain its leadership in the fiercely competitive obesity landscape.